Correspondence Regarding Novavax Agreement

Written by Claude Haiku 4.5 from the extracted text on 27 Feb 2026. It can miss or misread redacted and scanned pages. Check the source before relying on it.

As of April 2024, the Department of Finance's National COVID-19 Vaccine Program dashboard indicated overall program status was GREEN with medium-high delivery confidence. The vaccine supply workstream showed surplus supply extending to mid-2026, though Novavax supply gaps were forecast for 2025 with anticipated resumption in early 2025 and 2026. The department was actively negotiating with manufacturers to secure updated vaccine formulations, including JN.1 strain vaccines and pre-filled syringes for Q4 2024 delivery, with 2025 supply subject to regulatory approval. The NCVP Roadmap tracked program milestones through 2024, with the document noted as dynamic and subject to frequent updates to manage critical dependencies across future program elements.